The Pharma Patent Playbook: How to Build, Defend, and Monetize Drug IP That Actually Holds
A $2.23 billion bet on a molecule. A 90% chance it never reaches a patient. A 20-year patent clock that […]
Insights
The KSM Playbook: How Key Starting Material Decisions Shape Drug Programs, IP Portfolios, and Market Share
Introduction: The Decision That Happens Before Anyone Is Watching The pharmaceutical industry runs on headline milestones. The Phase III readout.
The Definitive Biopharmaceutical Freedom-to-Operate Playbook: From Scoping to Execution, Patent Thickets to Platform IP
Part I: The Strategic and Financial Imperative of FTO The $2.6 Billion Bet and the One Analysis That Protects It
Pharmaceutical Drug Naming: The Complete IP, Patent, and Brand Strategy Guide
1. Why Drug Naming Is an IP Function, Not a Marketing Task The name on the bottle is not chosen
Pharmaceutical Drug Naming: The Complete IP, Patent, and Brand Strategy Guide Read Post »
Google Patents for Drug Patent Research: The Definitive Analyst’s Playbook
Part I: The Economic Architecture of Pharmaceutical Intellectual Property 1.1 The Patent Bargain and Its Financial Consequences The pharmaceutical industry
Google Patents for Drug Patent Research: The Definitive Analyst’s Playbook Read Post »
Drug Patent Protection in Global Markets: The Strategic Playbook
For pharma IP teams, portfolio managers, R&D leads, and institutional investors who need a complete, jurisdiction-by-jurisdiction framework — not another
Drug Patent Protection in Global Markets: The Strategic Playbook Read Post »
Biologic Drug Patent Applications: The Complete IP Playbook for a Post-Amgen World
Part I: Why Biologic Patents Are a Different Animal A biologic patent application is not a harder version of a
Biologic Drug Patent Applications: The Complete IP Playbook for a Post-Amgen World Read Post »
A Strategic Guide to Patenting Drug Combinations
A deep-dive reference for IP teams, R&D leads, patent counsel, and portfolio managers navigating combination therapy exclusivity Section 1: Executive
A Strategic Guide to Patenting Drug Combinations Read Post »
Generic Drug Pricing: The Complete Playbook for IP Teams, Portfolio Managers, and Market Strategists
The Affordability Paradox: Why Thin Margins Are a Systemic Risk Generic drugs filled 91% of all U.S. prescriptions in 2022,
